SLC5A2 and chronic kidney disease: As discussed below, sodium–glucose cotransporter-2 (SGLT-2) inhibitors, and more recently non-steroidal mineralocorticoid receptor antagonists (nsMRAs), have been introduced as pharmacotherapeutic agents in CKD with (SGLT-2 inhibitors and nsMRAs) or without concurrent T2D (SGLT-2 inhibitors).